Drug Trial Radar · NCT07090330
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jul 18, 2025
Primary completion
Mar 25, 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Oruka Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
ORKA-001 Induction DoseDrug
ORKA-001 Induction Dose, administered by subcutaneous (SC) injection
PlaceboOther
Placebo administered by subcutaneous (SC) injection
ORKA-001 Maintenance DoseDrug
ORKA-001 Maintenance Dose, administered by subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16Time frame: Week 16
Locations
26 sites in 2 countries. Site status is shown where the registry gives one.
Oruka Therapeutics Investigative Site
Fountain Valley, California
Oruka Therapeutics Investigative Site
Los Angeles, California
Oruka Therapeutics Investigative Site
San Diego, California
Oruka Therapeutics Investigative Site
Santa Ana, California
Oruka Therapeutics Investigative Site
Santa Monica, California
Oruka Therapeutics Investigative Site
Cromwell, Connecticut
Oruka Therapeutics Investigative Site
Miami, Florida
Oruka Therapeutics Investigative Site
Rolling Meadows, Illinois
Oruka Therapeutics Investigative Site
Bowling Green, Kentucky
Oruka Therapeutics Investigative Site
Rockville, Maryland
Oruka Therapeutics Investigative Site
Boston, Massachusetts
Oruka Therapeutics Investigative Site
Detroit, Michigan
Oruka Therapeutics Investigative Site
New York, New York
Oruka Therapeutics Investigative Site
New York, New York
Oruka Therapeutics Investigative Site
Portland, Oregon
Oruka Therapeutics Investigative Site
Norfolk, Virginia
Oruka Therapeutics Investigative Site
Milwaukee, Wisconsin
Oruka Therapeutics Investigative Site
Edmonton, Alberta, Canada
Oruka Therapeutics Investigative Site
Edmonton, Alberta, Canada
Oruka Therapeutics Investigative Site
Surrey, British Columbia, Canada
Oruka Therapeutics Investigative Site
Hamilton, Ontario, Canada
Oruka Therapeutics Investigative Site
London, Ontario, Canada
Oruka Therapeutics Investigative Site
Markham, Ontario, Canada
Oruka Therapeutics Investigative Site
Peterborough, Ontario, Canada
Oruka Therapeutics Investigative Site
Toronto, Ontario, Canada
Oruka Therapeutics Investigative Site
Waterloo, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.